Yet that was the dynamic with Neurocrine, with prognosticators at H.C. Wainwright, Guggenheim, and UBS (NYSE: UBS) all getting simultaneously less bullish on the company's future. Of the trio ...

Neurocrine Biosciences (NASDAQ:NBIX – Free Report) had its price objective reduced by Guggenheim from $165.00 to $163.00 in a report published on Monday,Benzinga reports. They currently have a ...

Of the trio, the most drastic cutter was UBS's Ashwani Verma, who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance ...

In a report released on February 7, Cory Kasimov from Evercore ISI maintained a Buy rating on Neurocrine (NBIX – Research Report), with a price target of $190.00. The company’s shares closed ...

Furthermore, Neurocrine's lower-than-expected 2025 guidance for Ingrezza—a range of $2.5 billion to $2.6 billion—left investors puzzled and shares spiraling.

It's been a soft week for Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares, which are down 19%. But we wouldn't complain about the gain over the last three years. In that time the stock gained 43 ...

Deutsche Bank initiated coverage of Neurocrine (NBIX) with a Hold rating and $138 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Free Report)’s share price traded down 4.9% on Monday after Guggenheim lowered their price target on the stock from $165.00 to $163.00.

Does Warren Buffett Know Something That Wall Street Doesn't? The Billionaire Investor Is Piling Into a High-Yield Stock That Certain Analysts Recommend Selling. Mark Cuban's $400K Bet On Teen ...

In this article, we are going to take a look at where Neurocrine Biosciences Inc. (NASDAQ:NBIX) stands against the other stocks. Ten companies were hit hard on Friday as investors digested ...